News from wuxi biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

06 Aug, 2020, 10:00 BST WuXi Vaccines Appoints Mr. Jian Dong as Chief Executive Officer

WuXi Vaccines, a global leading company with world-class vaccine contract development and manufacturing organization (CDMO) capabilities, is pleased...


16 Jun, 2020, 01:00 BST WuXi Biologics (Suzhou) Received EMA GMP Certificate for Biosafety Testing

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its facility in...


14 Apr, 2020, 01:00 BST WuXi Biologics (Suzhou) Successfully Passed First EMA GMP Inspection

WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platform, announced that WuXi Biologics...


24 Feb, 2020, 00:17 GMT WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


18 Feb, 2020, 10:58 GMT WuXi Biologics' Subsidiary WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


18 Feb, 2020, 10:33 GMT WuXi Vaccines Signed Long-Term Vaccine Manufacturing Contract with a Global Vaccine Leader

WuXi Vaccines, a new vaccine Contract Development and Manufacturing Organization (CDMO) established between WuXi Biologics (stock code: 2269.HK) and...


12 Feb, 2020, 00:00 GMT WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak

WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to...


29 Jan, 2020, 02:24 GMT WuXi Biologics Provides Operation Update Related to the Coronavirus Outbreak

The coronavirus outbreak is having a potentially significant social and economic impact in China. WuXi Biologics is closely monitoring the...


29 Jan, 2020, 01:18 GMT WuXi Biologics Enables Development of Multiple Neutralizing Antibodies for Novel Coronavirus

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


16 Jan, 2020, 03:13 GMT WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


09 Jan, 2020, 10:09 GMT WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


23 Dec, 2019, 08:42 GMT WuXi Biologics Receives "Special Award to Investors in Ireland" from Asia Matters

December 23, 2019 – WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end...


22 Nov, 2019, 17:33 GMT WuXi Vaccines to Build a $240 Million Manufacturing Facility in Ireland

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


19 Nov, 2019, 01:09 GMT WuXi Biologics Congratulates Tychan on the World's First Yellow Fever Antibody Tested Safe and Efficacious in Human Volunteers

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


09 Apr, 2019, 06:00 BST WuXi Biologics and NBE-Therapeutics Announce Comprehensive ADC Development and Manufacturing Partnership

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


20 Mar, 2019, 00:19 GMT WuXi Biologics Receives EMA GMP Certificates

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


19 Feb, 2019, 06:49 GMT EMA Completed Pre-Approval Inspection of cGMP DS and DP Facilities for Trogarzo (TM) at WuXi Biologics

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics ...


11 Dec, 2018, 07:00 GMT Oxford BioTherapeutics Expands Strategic Collaboration with WuXi Biologics and Licenses WuXiBody™ Platform for Five Bispecific Antibody Programs for up to $450 Million

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...


05 Dec, 2018, 15:09 GMT WuXi Biologics Commenced Construction of the Largest Biomanufacturing Facility Using Single-Use Bioreactors in Ireland

WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery,...